drugset / Trial / NCT02460133
Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment
Phase 4
Active not recruiting
44 enrolled
Nova Scotia Health Authority
Provincial Correction Centre (PEI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This pilot study is crucial to determining whether treating individuals who are at high risk for transmission or re-infection will impact HCV reinfection rates. It will establish the feasibility of DAA treatment in corrections facilities, as well as delineate the underlying immune basis of HCV cure and reinfection.
Timeline
- Start
- 2015-07-10
- Primary completion
- 2025-10
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribavirin | Small molecule | — | — |
| Subject | Ritonavir | Other / unclassified | — | — |
| Subject | dasabuvir | Small molecule | — | — |
| Subject | ombitasvir | Small molecule | — | — |
| Subject | paritaprevir | Small molecule | — | — |